» Articles » PMID: 25427992

Immune Thrombocytopenic Purpura (ITP) Associated with Vaccinations: a Review of Reported Cases

Overview
Journal Immunol Res
Date 2014 Nov 28
PMID 25427992
Citations 72
Authors
Affiliations
Soon will be listed here.
Abstract

Immune thrombocytopenic purpura (ITP) is an autoimmune condition characterized by low platelet count with mucocutaneous and other bleedings. Clinical manifestations may range from spontaneous formation of purpura and petechiae, especially on the extremities, to epistaxis, bleeding at the gums or menorrhagia, any of which occur usually if the platelet count is below 20,000 per μl. A very low count may result in the spontaneous formation of hematomas in the mouth or on other mucous membranes. Fatal complications, including subarachnoid or intracerebral, lower gastrointestinal or other internal bleeding can arise due to an extremely low count. Vaccines may induce ITP by several mechanisms. Vaccine-associated autoimmunity may stem not only from the antigen-mediated responses but also from other constituents of the vaccine, such as yeast proteins, adjuvants, and preservatives diluents. The most likely is through virally induced molecular mimicry. The binding of pathogenic autoantibodies to platelet and megakaryocytes may cause thrombocytopenia by different mechanisms, such as opsonization, direct activation of complement, or apoptotic pathways. The autoantibodies hypothesis is not sufficient to explain all ITP cases: In the anti-platelet antibody-negative cases, a complementary mechanism based on T cell immune-mediated mechanism has been suggested. In particular, T cell subsets seem dysregulated with an increased production of pro-inflammatory cytokines, as IFN-γ and TNF, and chemokines, as CXCL10. Vaccines are one of the most striking discoveries in human history that changed dramatically life expectancy. Nonetheless, the occurrence of adverse events and autoimmune phenomena has been described following vaccination, and ITP may represent one of this.

Citing Articles

Immune thrombocytopaenic purpura following the second dose of Pfizer COVID-19 vaccine.

Latef T, Howard L, Loke C, Tsui E BMJ Case Rep. 2025; 15(9).

PMID: 39901382 PMC: 9442476. DOI: 10.1136/bcr-2022-249477.


Impact of administration routes and dose frequency on the toxicology of SARS-CoV-2 mRNA vaccines in mice model.

Ahn J, Lee J, Roh G, Lee N, Bae H, Kwon E Arch Toxicol. 2024; 99(2):755-773.

PMID: 39656241 PMC: 11775000. DOI: 10.1007/s00204-024-03912-1.


The Impact of COVID-19 Vaccination on Oxidative Stress and Cardiac Fibrosis Biomarkers in Patients with Acute Myocardial Infarction (STEMI), a Single-Center Experience Analysis.

Al Namat R, Duceac L, Chelaru L, Dimitriu C, Bazyani A, Tarus A Life (Basel). 2024; 14(11).

PMID: 39598149 PMC: 11595417. DOI: 10.3390/life14111350.


Two Cases of Immune Thrombocytopenia (ITP) Related to Viral Vector Vaccination ChAdOx1-S (AstraZeneca) and a Good Response after Thrombopoietin Receptor Agonist (TPO-RA) Therapy.

Salveridou K, Tzamalis T, Klaiber-Hakimi M, Haase S, Gropper S, Giagounidis A Hematol Rep. 2024; 16(4):585-592.

PMID: 39449300 PMC: 11503447. DOI: 10.3390/hematolrep16040057.


Immune thrombocytopenic purpura after influenza vaccine administration; a systematic review and meta-analysis.

Elsaid M, Nune A, Brakat A, Anand A, Alashwah M, Maher A Trop Dis Travel Med Vaccines. 2023; 9(1):22.

PMID: 38001495 PMC: 10675976. DOI: 10.1186/s40794-023-00206-9.


References
1.
Nieminen U, Peltola H, Syrjala M, Makipernaa A, Kekomaki R . Acute thrombocytopenic purpura following measles, mumps and rubella vaccination. A report on 23 patients. Acta Paediatr. 1993; 82(3):267-70. DOI: 10.1111/j.1651-2227.1993.tb12657.x. View

2.
Yasuda H, Nagata M, Moriyama H, Kobayashi H, Akisaki T, Ueda H . Development of fulminant Type 1 diabetes with thrombocytopenia after influenza vaccination: a case report. Diabet Med. 2011; 29(1):88-9. DOI: 10.1111/j.1464-5491.2011.03391.x. View

3.
Arkfeld D, Weitz I . Immune thrombocytopenia in patients with connective tissue disorders and the antiphospholipid antibody syndrome. Hematol Oncol Clin North Am. 2009; 23(6):1239-49. DOI: 10.1016/j.hoc.2009.08.010. View

4.
Rocha A, Souza C, Rocha G, de Melo F, Clementino N, Marino M . The levels of IL-17A and of the cytokines involved in Th17 cell commitment are increased in patients with chronic immune thrombocytopenia. Haematologica. 2011; 96(10):1560-4. PMC: 3186321. DOI: 10.3324/haematol.2011.046417. View

5.
Olsson B, Andersson P, Jernas M, Jacobsson S, Carlsson B, Carlsson L . T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med. 2003; 9(9):1123-4. DOI: 10.1038/nm921. View